Furthermore, identification of FOXA2 as specific enhancing protein might be useful as therapeutic target to increase the expression of AGC2 in patients with type II citrullinemia showing a mild phenotype, as reported for other mitochondrial carrier deficiencies [58]. Here, FOXA2 is linked to citrullinemia type II.